Karen Knudsen, MD
Endocrinology, Diabetes & Metabolism · Williamsburg, VANPI 1659574309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,098 and has fallen 63.8% since, to $759 in 2025.
Across 267 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$811
- AstraZeneca$710
- Insulet Corporation$653
- Novo Nordisk$524
- Radius Health, Inc.$379
- AbbVie$374
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,71299%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $811 |
| AstraZeneca(2 entities) | 22 | $710 |
| Insulet Corporation | 18 | $653 |
| Novo Nordisk | 23 | $524 |
| Radius Health, Inc. | 26 | $379 |
| AbbVie | 20 | $374 |
| Abbott | 6 | $351 |
| Amgen(2 entities) | 11 | $269 |
| Merck | 15 | $244 |
| Boehringer Ingelheim | 11 | $209 |
| Dexcom, Inc. | 7 | $132 |
| Amneal Pharmaceuticals LLC | 6 | $104 |
| Xeris Pharmaceuticals, Inc. | 5 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Tandem Diabetes Care, Inc. | 5 | $85 |
| Antares Pharma, Inc. | 4 | $80 |
| Mannkind Corporation | 4 | $75 |
| Shire North American Group Inc | 4 | $64 |
| Medtronic(2 entities) | 4 | $59 |
| Johnson & Johnson(2 entities) | 3 | $58 |
| Pfizer | 3 | $51 |
| Sequel Med Tech, LLC | 2 | $47 |
| BETA Bionics, Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $43 |
| Senseonics, Incorporated | 1 | $32 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Cequr Corporation | 1 | $21 |
| Valeritas, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $12 |
| Mission Pharmacal Company | 1 | $12 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,770 in reported general payments places this provider in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $114,480 |
| JardianceEmpagliflozin | 41 | $61,771 |
| TrulicityDulaglutide | 38 | $60,544 |
| FarxigaDapagliflozin Propanediol | 26 | $38,280 |
| MounjaroTirzepatide | 23 | $33,128 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $29,471 |
| SynthroidLevothyroxine Sodium | 243 | $20,682 |
| JanuviaSitagliptin Phosphate | 13 | $15,720 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $12,897 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $10,736 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $10,255 |
| HumalogInsulin Lispro | 16 | $8,124 |
| NovologInsulin Aspart | 20 | $7,582 |
| Novolog FlexpenInsulin Aspart | 16 | $6,736 |
| Levothyroxine Sodium | 316 | $5,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $524 | $122,06273 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $811 | $104,37293 claims |
| Boehringer IngelheimJardiance | $209 | $61,77141 claims |
| AstraZenecaFarxiga | $710 | $38,28026 claims |
| AbbVieSynthroid | $374 | $20,682243 claims |
| MerckJanuvia | $244 | $15,72013 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $104 | $5,688328 claims |
| IBSA Pharma Inc.Tirosint | $43 | $4,35211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Williamsburg
- Katherine RobertsWilliamsburg$5K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.